Nigeria: With 26 Percent Growth in H1, Neimeth Outshines Peers in Revenue Generation

Neimeth International Pharmaceuticals Plc has emerged as the fastest-growing listed pharmaceutical company by revenue in the first half of 2026, recording a 26 per cent year-on-year increase in sales. Despite the challenging operating environment, marked by high borrowing costs, inflationary pressures, and foreign exchange volatility, Neimeth delivered the strongest top-line growth among its peers.

The company's revenue rose to N3.66 billion in the six months ended June 30, 2026, from N2.91 billion recorded in the corresponding period of 2025, underscoring its ability to expand sales and maintain profitability despite operating from a smaller asset and production base than its larger competitors.

Brief written by urgent.news from AllAfrica Health's own syndicated text. Machine-written — it may contain errors, so check the original before relying on it.